Algernon Pharmaceuticals Inc
Algernon Health Inc. operates as a clinical stage pharmaceutical development company in Canada and Australia. The company focuses on developing the therapeutic drugs in the areas of non-alcoholic steatohepatitis, liver disease, chronic kidney disease, and stroke program. Its pipeline includes repirinast for the treatment of chronic kidney disease; and N,N-Dimethyltryptamine for the treatment of s… Read more
Algernon Pharmaceuticals Inc (AGNPF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of November 2025: -0.144x
Based on the latest financial reports, Algernon Pharmaceuticals Inc (AGNPF) has a cash flow conversion efficiency ratio of -0.144x as of November 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-356.91K) by net assets ($2.49 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Algernon Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Algernon Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Algernon Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Algernon Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Etga Group Ltd
TA:ETGA
|
0.014x |
|
OBAL11
SA:OBAL11
|
N/A |
|
WestKam Gold Corp
PINK:WKGFF
|
0.065x |
|
STAGEZERO LIFE SCIENC.
F:61N1
|
N/A |
|
CLASS 1 NICKEL+TECH.LTD
F:77C
|
N/A |
|
Identitii Ltd
AU:ID8
|
-0.536x |
|
Prima Alloy Steel Universal
JK:PRAS
|
0.006x |
|
Webco Industries Inc
PINK:WEBC
|
-0.026x |
Annual Cash Flow Conversion Efficiency for Algernon Pharmaceuticals Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Algernon Pharmaceuticals Inc from 2016 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-08-31 | $2.70 Million | $-1.16 Million | -0.429x | +65.64% |
| 2024-08-31 | $2.17 Million | $-2.71 Million | -1.249x | +27.86% |
| 2023-08-31 | $1.47 Million | $-2.55 Million | -1.732x | -234.48% |
| 2022-08-31 | $5.62 Million | $-2.91 Million | -0.518x | +39.66% |
| 2021-08-31 | $9.12 Million | $-7.82 Million | -0.858x | -58.62% |
| 2020-08-31 | $12.22 Million | $-6.61 Million | -0.541x | -50.96% |
| 2019-08-31 | $4.97 Million | $-1.78 Million | -0.358x | +20.60% |
| 2018-08-31 | $1.37 Million | $-616.51K | -0.451x | +41.27% |
| 2017-08-31 | $1.59 Million | $-1.22 Million | -0.768x | -15.89% |
| 2016-08-31 | $2.12 Million | $-1.41 Million | -0.663x | -- |